Completion of Share Acquisition of Amato Pharmaceutical Products, Ltd. by ROHTO

ROHTO Pharmaceutical Co., Ltd. (hereinafter "ROHTO") is pleased to announce that the acquisition of 67.19% (860,000 shares) of the issued shares of Amato Pharmaceutical Products, Ltd. (hereinafter "Amato Pharmaceutical") has been completed on August 31. As a result, Amato Pharmaceutical has become a subsidiary of ROHTO, with the goal of expanding its operations in the over-the-counter (OTC) sector, specifically general pharmaceuticals.

Founded in 1921 as the Amato Pharmaceutical Chemical Research Institute, Amato Pharmaceutical has a history rooted in the development of "Boraginol®," an innovative drug for hemorrhoids introduced in the same year. The company was restructured as Amato Pharmaceutical Products, Ltd. in 1950, and for a century since its establishment, it has continuously manufactured and sold this product.

Through this share acquisition, ROHTO aims to leverage Amato Pharmaceutical's technology and combine it with ROHTO's overseas subsidiaries' sales networks and marketing expertise. This synergistic approach will drive further business expansion, contribute to the well-being of individuals, and work towards realizing healthier and happier lives for all.